Stage 4 CKD presentation in patients over 75 Years Old differs from that in patients less than 75 Years of Age Hiromichi Suzuki, Tsutomu Inoue,Tomohiro.

Slides:



Advertisements
Similar presentations
The National Kidney Foundations Kidney Early Evaluation Program TM The National Kidney Foundations Kidney Early Evaluation Program TM Essex-Passaic Wellness.
Advertisements

Chronic Kidney Disease Manju Sood GPST3. What is CKD? Chronic renal failure is the progressive loss of nephrons resulting in permanent compromise of renal.
ESRD Registry Committee, Korean Society of Nephrology*
SLOW- COOKING THE BEANS “OR, HOW TO STOP WORRYING AND APPLY SOME LOVE TO THE KIDNEYS” AN APPROACH TO CKD SARA KATE LEVIN, MD JANUARY 2014.
CKD In Primary Care Dr Mohammed Javid.
National Institute for Health and Clinical Excellence.
Chapter 1: CKD in the General Population 2014 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
RENAL BLOOD TESTS WHAT DO THEY MEAN, WHERE TO GO FOR WHAT TO DO.
K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.
A retrospective cohort study of Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease in later life Andrew V White,
Mugendi AG, BPharm, MPharm (Clin Pharm). Comparison of the effects of losartan and enalapril on renal function in adults with chronic kidney disease at.
Chapter 2: Identification and Care of Patients With CKD 2014 ANNUAL DATA REPORT VOLUME 1: CHRONIC KIDNEY DISEASE.
Reference Cooper BA, and the IDEAL study group. A randomized controlled trial of early versus late initiation of dialysis. N Engl J Med [Accessed.
Effect of High-dose Angiotensin II Receptor Blocker (ARB) Monotherapy versus ARB plus Calcium Channel Blocker Combination on Cardiovascular Events in Japanese.
A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.
RENAL DISEASE IN DIABETES
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Health Care Costs Associated with Chronic Kidney Disease in Patients with Type II Diabetes Zita Shiue, MD Internal Medicine, R3 Chief of Medicine Conference.
6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
Primary Aim To compare outcomes of participants with symptoms of stable angina or angina equivalent evaluated with an anatomic imaging strategy using CCTA.
Clinical Appraisal of an Article on Prognosis The Clinical Question Will the prognosis of patients with gout be affected by the administration allupurinol?
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
The National Kidney Foundation’s Kidney Early Evaluation Program TM “The Greater New York Experience” Ellen H. Yoshiuchi, MPS Division Program Director.
Definitions and classification of office blood pressure levels (mmHg) Modified by ESC Guidelines 2013 CARDIOcheckAPP.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
William C. Cushman, MD, FACP, FAHA Veterans Affairs Medical Center, Memphis, TN For The ACCORD Study Group.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Case Report and Lit Review: Reduction of Proteinuria in Diabetic Nephropathy with Spironolactone Harry W. Floyd, M.D. Family Medicine Kingstree, South.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Chapter 1: CKD in the General Population 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
Chapter 2: Identification and Care of Patients With CKD 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Early Eplerenone Treatment in Patients with Acute ST-elevation Myocardial Infarction without Heart Failure REMINDER* Gilles Montalescot, Bertram Pitt,
Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease S Bianchi, R Bigazzi and VM Campese Kidney.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
A Randomized Trial of Intensive versus Standard Blood-Pressure Control The SPRINT Research Group* November 9, /NEJMoa R2 이성곤 /pf. 우종신.
Left Ventricular Filling Pressure by Doppler Echocardiography in Patients With End-Stage Renal Disease Angela Y-M Wang, Mei Wang, Christopher W-K Lam,
Prevalence of Chronic Kidney Disease in an Urban Population
Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive.
1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.
Original article Chronic Renal Failure A Neglected Comorbidity of COPD Raffaele Antonelli Incalzi, MD; Andrea Corsonello, MD; Claudio Pedone, MD; Salvatore.
Anemia in CKD The TREAT Trial Reference Pfeiffer MA. A trial of Darbepoetin alpha in type II diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019–2032.
Powered by Infomedica Infomedica Conference Coverage* of 26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13,
Figure 1.1 Prevalence of CKD by stage among NHANES participants,
Nephrology Journal Club The SPRINT Trial Parker Gregg
Alcohol, Other Drugs, and Health: Current Evidence July–August 2017
The LIVES Sub-analysis
Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:
All-cause mortality by treatment group
2016 Annual Data Report, Vol 1, CKD, Ch 2
Chapter 1: CKD in the General Population
CARDIOVASCULAR CORELATIONS IN CHILDREN WITH END STAGE RENAL DISEASE
First time a CETP inhibitor shows reduction of serious CV events
Systolic Blood Pressure Intervention Trial (SPRINT)
The percentage of subjects with de novo development of renal function impairment (GFR
Progress and Promise in RAAS Blockade
Chapter 1: CKD in the General Population
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
National Quality Assessment Evaluating Spironolactone Use During Hospitalization for Acute Myocardial Infarction (AMI) in China: China Patient-centered.
Giuseppe Biondi Zoccai, MD
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Volume 79, Pages S9-S13 (April 2011)
American Journal of Kidney Diseases
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
UK Renal Registry 10th Annual Report 2007
Areef Ishani, Allan J. Collins, Charles A. Herzog, Robert N. Foley 
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Presentation transcript:

Stage 4 CKD presentation in patients over 75 Years Old differs from that in patients less than 75 Years of Age Hiromichi Suzuki, Tsutomu Inoue,Tomohiro Kikuta, Yusuke Watanabe, Hirokazu Okada Department of Nephrology, Saitama Medical University

Nephro-2014 COI Author Hiromichi Suzuki Conflict of Interest The authors declare that they have no conflict of interest in this study.

Introduction The proportion of older people in the general population is steadily increasing and the fastest growing segment of that population during the past decade is older than 75 years. With this increases in prevalence of elderly people, proportion of prevalent chronic kidney disease (CKD) increased in parallel. In spite of these situations, the appropriate treatment of older patients with CKD remains unclear. Moreover, there are a lot of unresolved problems in real world.

Aim The aim of this study is to evaluate the prognosis of patients >75 years in comparison with those between 74 and 65 years, the longitudinal follow-up of elderly patients with CKD stage 4 was carried out in a single center and to characterize patients with CKD stage 4 older than 75 years.

Patients and Methods I Patients were recruited from specialist renal clinics at Renal Disease Center, Saitama Medical University from January 2004 to December All participating patients were followed for 5 years or until death, commencement of dialysis therapy, receiving renal transplantation, finding of neoplasm, or occurrence of a cardiovascular event (fatal or non-fatal myocardial infarction, cerebrovascular disease, aortic dissection).

Patients and Methods II Inclusion criteria were CKD as defined by K/DOQI, not yet on dialysis, stable renal function within the last 3 months (<5 mL/min/1.73 m2 change in GFR), and no change in medication in the preceding 3 months. Exclusion criteria included known left ventricular dysfunction (ejection fraction <55%), or signs and symptoms of congestive heart failure, significant valvular or coronary heart disease, and use of sedative or hypnotic drugs or any other drugs potentially affecting blood pressure during ambulatory monitoring, e.g., corticosteroids.

Definition Late referral was defined as the patients who were referred from general physician based clinic during the recruitment of this study. The cause of CKD was assessed by reviewing the clinical history and investigations. Patients were classified as “hypertensive/glomerulosclerosis” if the patients had no clear evidence of active renal disease but had a history of hypertensive diseases and positive urinary protein excretion without casts. DM was defined as HbA1c 5.8% or higher, or taking antidiabetics including insulin. GN was defined by biopsy or clinical diagnosis such as urine casts including unregulated red cells.

Patients Characteristics VariablesYounger GroupElderly Group N=179N=106 Age (years)70.8± ±2.6* Male (%)106/7358/48 eGFR (ml/min/1.73m2)21.6± ± 4.1 Underlying disease(male/female)(%) DM91 (60/31)(51)24**(15/7)(23) GN41 (25/16)(23)24 (17/9)(23) HT44 (18/26)(24)54**(25/29)(51) others3 (3/0)(2)4 (1/3)(3) Late Referral (male/female) (%)44 (28/16)(25)23 (11/12)(22) eGFR, estimated glomerular filtration; DM, diabetic nephropathy; GN, glomerular nephritis; HT, hypertensive nephrosclerosis. ** indicates P<0.01 compared with younger group.

Young Elderly mL/min/1.73m 2 Comparison of eGFR between patients in younger and elderly group

Comparison of underlying disease of patients between younger and elderly group DM GN HT others **

Baseline characteristics of the study population VariablesYounger(N=179)Elderly (N=106) SBP (mmHg)137.5 ± ± 18.3 DBP (mmHg)81.9 ± ± 6.5* HR (beats/min)72.3 ± ± 5.4 Serum albumin (g/dL)4.0 ± ± 0.6 Hemoglobin (g/dL)11.6 ± ± 0.8 Total cholesterol (mg/dL)189.2 ± ± 46.3 Phosphate (mg/dL)4.1 ± ± 1.5 Calcium (mg/dL)9.1 ± ± 1.0 Urinary protein excretion (g/gCr)1.34 ± ± 0.90 SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate. * indicates P<0.05 compared with younger group.

Comparison of variables between DM and non DM nephropathy VariablesDM nephropathyNon DM nephropathy N=105N=170 75<75>75<75> eGFR (ml/min/1.73m2)21.4± ± ± ± 4.5 SBP (mmHg)121.6± ± ± ± 19.5 DBP (mmHg)82.4 ± ± 16.6*82.6± ± 12.5* HR (beats/min)71.4± ± ± ± 6.3 Serum albumin (g/dL)4.0 ± ± ± ± 0.6 Hemoglobin (g/dL)12.4 ± ± ± ± 0.8 Total cholesterol (mg/dL)189.2 ± ± ± ± 38.7 Phosphate (mg/dL)3.7 ± ± ± ± 0.9 Calcium (mg/dL)9.2 ± ± ± ± 0.4 Urinary protein excretion (g/gCr)1.34 ± ± ± ± 1.15 HbA1C (%)6.3± ± ± 0.3**5.1± 0.6** SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate. *indicates P<0.05 compared with the values of younger group and ** indicates P<0.01 compared with the patients with DM nephropathy

Comparison of underlying disease of patients between total population and late referral DM GN HT others **

Total Late mL/min/1.73m 2 Comparison of eGFR between patients in total population and late referral

VariablesTotal (N=218)Late referral (N=67) Age (years)75<75>75<75> Gender (male/female)135(78/57)83(47/36)44 (28/16)23 (11/12) eGFR (mL/min/1.73 m2)21.7± ± ± ± 4.9 SBP (mmHg)128.6 ± ± ± ± 11.9 DBP (mmHg)81.5 ± ± ± ± 11.4 HR (beats/min)72.3 ± ± ± ± 7.2 Serum albumin (g/dL)4.1 ± ± ± ± 1.2 Hemoglobin (g/dL)12.6 ± ± ± ± 0.9 Total cholesterol (mg/dL)200.6± ± ± ± 35.3 Phosphate (mg/dL)3.6± ± ± 1.8*4.8± 0.7* Calcium (mg/dL)9.6 ± ± ± 1.1*8.4± 1.5* Urinary protein excretion (g/gCr)1.12 ± ± ± ± 1.21 Comparison of baseline characteristics between total population and patients with late referral

Comparison of events between patients in younger and elderly group RRT MI CVD Heart failure Neoplasma others **

Kaplan Meier curve of event free for patients in younger and elderly group Event free 0 (month) Elderly Younger Event free

Comparison of events between patients with diabetic nephropathy and non diabetic nephrophathy RRT MI CVD Heart failure Neoplasma others **

Event free 0 (month) Kaplan Meier Curve of event free in patients with diabetic nephropathy and non diabetic nephropahty Non DM DM

Comparison of events between total population and late referral patients RRT MI CVD Heart failure Neoplasma others **

Event free 0 (month) Kaplan Meier curve of event free in late referral patients and total population Total Late referral

Selection of Modalities of Dialysis Therapy *

Selection of Modalities Number

In Summary 1.This 5-year prospective observation study demonstrated that, if elderly people>65 years is divided into 2; and >75 years in CKD patients, a proportion of the underlying renal disease was completely different. In the elderly patients >75 years, HT nephrosclerosis and GN were predominant. In contrast, in the patients 65 to 74 years, DM nephropathy was predominant. 2. The ratio of development to RRT was higher in the patients 65 to 74 years, probably being due to a large proportion of DM nephropathy as the leading cause of renal disease. 3. A prognosis of DM nephropathy, regardless of age groups, was poor. 4. A prognosis of the late referral patients was also not well.

Conclusion In conclusion, it is suggested that in the patients >75 years, the values of eGFR may be overestimated and a prognosis of DM nephropathy was poor. And lastly, the early nephrology referral is encouraged.

Thank you for your attention. We are here.